The average market capitalization of the top quoted biotechnology companies in each of the various European markets declined by between 20% and 45% in the year beginning September 1, 2001. (Average market cap in each territory is calculated by averaging the share price of the highest cap biotech companies in that territory and multiplying by the total number of outstanding shares, see details on chart.) Although the average decrease in market cap among the 16 European companies surveyed is 44.5%, there are noticeable geographic variations.
The German market has been the hardest hit, with a mean 55% loss in market cap, reflecting the relative immaturity...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?